USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES - Quality by Design for Biopharmaceuticals - page 77

Figure 4.22. Cotton rat PK study: levels of motavizumab in serum after dosing.
Figure 4.23. Cotton rat PK study measuring levels of motavizumab in BAL after dosing.
Motavizumab is undetectable at 21 days.
Figure 4.24. Cotton rat PK study measuring levels of motavizumab in lung homogenate after
dosing. Motavizumab is undetectable at 21 days.